Abstract
Prostaglandin E1 (PGE1, alprostadil) is essential in managing ductus-dependent
congenital heart defects (CHD) in neonates. Although its common adverse effects
are well documented, dermatologic manifestations remain rare and
underrecognized. We report a term male neonate with a prenatal diagnosis of
complex critical CHD who required PGE1 infusion and subsequently developed an
annular migratory rash on the third postnatal day. The rash resolved within
minutes of PGE1 dose reduction but recurred upon dose escalation, strongly
suggesting a causal link. Following surgical palliation and discontinuation of
PGE1, the skin findings resolved completely and did not recur. This case
underscores a rare but distinctive cutaneous reaction to PGE1 therapy and
highlights the importance of early recognition to avoid unnecessary diagnostic
testing and interruption of life-saving treatment.
Keywords
Congenital Heart Disease - Prostaglandin E1 - Newborn - Migratory Rash - Side effect
